Vertex announces fda clearance of investigational new drug (ind) application for vx-880, a novel cell therapy for the treatment of type 1 diabetes (t1d)

Boston--(business wire)--vertex pharmaceuticals incorporated (nasdaq: vrtx) today announced that the u.s. food and drug administration (fda) has cleared the ind, enabling the company to proceed with initiating a clinical trial for vx-880, an investigational stem cell-derived, fully differentiated pancreatic islet cell therapy to treat t1d. vertex plans to initiate a phase 1/2 clinical trial in the first half of 2021 in patients who have t1d with impaired hypoglycemic awareness and severe hypogl
VRTX Ratings Summary
VRTX Quant Ranking